2-(4-methoxy-3-nitrophenyl)ethane-1-amine | 858855-65-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-methoxy-3-nitrophenyl)ethane-1-amine
• 英文别名: 2-(4-methoxy-3-nitrophenyl)ethanamine；(4-methoxy-3-nitrophenyl)ethaneamine；4-methoxy-3-nitro-phenethylamine；4-Methoxy-3-nitro-phenaethylamin；3-Nitro-4-methoxy-β-phenaethylamin
• CAS: 858855-65-9
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: VVURPGSRPLBVFO-UHFFFAOYSA-N

物化性质

• 沸点：
  356.1±27.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-methoxy-3-nitrophenyl)ethane-1-amine 在 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 11.0h， 生成 [3-[2-[2-[3-(Ethoxycarbonylamino)-4-methoxyphenyl]ethylamino]-2-oxoethyl]-2-(hydroxymethyl)-6-methoxyphenyl] benzenesulfonate
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY
  [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA NASH, DE LA NAFLD ET DE L'OBÉSITÉ

  摘要：

  目前的技术涉及使用I、II、III、IV、V和/或VI式化合物治疗NASH、NAFLD和/或肥胖的方法。这些方法包括向患有非酒精性脂肪肝炎（NASH）、非酒精性脂肪肝病（NAFLD）和/或肥胖的受试者施用这种化合物的治疗有效剂量。

  公开号：

  WO2021067490A1
• 作为产物：
  描述：

  (4-hydroxy-3-nitro-phenyl)-acetic acid amide 在 硼烷四氢呋喃络合物 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 2-(4-methoxy-3-nitrophenyl)ethane-1-amine
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY
  [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA NASH, DE LA NAFLD ET DE L'OBÉSITÉ

  摘要：

  目前的技术涉及使用I、II、III、IV、V和/或VI式化合物治疗NASH、NAFLD和/或肥胖的方法。这些方法包括向患有非酒精性脂肪肝炎（NASH）、非酒精性脂肪肝病（NAFLD）和/或肥胖的受试者施用这种化合物的治疗有效剂量。

  公开号：

  WO2021067490A1

文献信息

• Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
  申请人：Liu Haiyan

  公开号：US20110009628A1

  公开（公告）日：2011-01-13

  The present technology relates to compounds of Formulas I-VI and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also increase HDL-C, lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.

  目前的技术涉及到公式I-VI的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还可以增加高密度脂蛋白胆固醇（HDL-C），降低总胆固醇、低密度脂蛋白胆固醇（LDL-C）和甘油三酯，并增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活蛋白激酶。
• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。
• [EN] CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS<br/>[FR] DÉRIVÉS DE CORYDALINE UTILES DANS LA RÉDUCTION DES TAUX LIPIDIQUES
  申请人：CVI PHARMACEUTICALS LTD

  公开号：WO2010075469A1

  公开（公告）日：2010-07-01

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.

  目前的技术涉及到公式（V）和（VI）的化合物以及制备和使用这些化合物的方法。使用方法包括预防和治疗高脂血症、高胆固醇血症、高甘油三酯血症、肝脂肪变性和代谢综合征。本文披露的化合物还能降低总胆固醇、LDL-胆固醇和甘油三酯，增加肝LDL受体表达，抑制PCSK9表达，并激活AMP激活的蛋白激酶。
• PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS
  申请人：Shanghai Zhimeng Biophama Co., Ltd.

  公开号：US20190152963A1

  公开（公告）日：2019-05-23

  The present invention discloses a pyrazole-oxazolidinone compound having anti-hepatitis B virus activity, which has the structure of formula (I), wherein each variable is as defined herein.

  本发明公开了一种具有抗乙型肝炎病毒活性的吡唑-噁唑烷酮化合物，其具有如下式（I）的结构，其中每个变量如本文所定义。
• Pro-atrial natriuretic peptide hormone from right atria is correlated with cardiac depression in septic patients
  作者：Branka Mazul-Sunko、N. Zarkovic、N. Vrkic、R. Klinger、M. Peric、M. Bekavac-Beslin、M. Novkoski、A. Krizmanic、A. Gvozdenovic、E. Topic

  DOI：10.1007/bf03343878

  日期：2001.7

  N-terminal pro-atrial natriuretic peptide [proANP(1-98)] has been extensively investigated in patients with chronic heart failure and ishemic heart disease. It is found to be a better marker of cardiac dysfunction than atrial natriuretic peptide (ANP). The possible involvement of proANP(1-98) in cardiac depression caused by sepsis has not been studied yet. Therefore, we analyzed atrial plasma concentration of proANP(1-98) in 17 septic patients with hemodynamic variables measured or calculated using pulmonary artery catheter, The results of altogether 96 measurements show a significant negative correlation of proANP(1-98) and cardiac index (p<0.024), oxygen delivery (p<0.03) and oxygen consumption (p<0.03), There is also a positive correlation with pulmonary vascular resistance (p<0.03). ProANP(1-98) is significantly higher in patients who developed acute respiratory distress syndrome (ARDS) (p<0.001), This study implies that proANP(1-98) is a possible novel hormone marker of cardiac depression caused by sepsis that could be used for prediction of ARDS. (J. Endocrinol. Invest, 24: RC22-RC24, 2001) (C) 2001, Editrice Kurtis.